13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

128 trials found

diseases per page:

Showing 1 to 10 of 128 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03283397 (ClinicalTrials.gov)	March 26, 2019	12/9/2017	A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of ...	A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Ar ...	Multiple Sclerosis, Relapsing-Remitting	Drug: EK-12;Drug: INF beta-1a	Bosnalijek D.D	MonitorCRO	Recruiting	18 Years	55 Years	All	400	Phase 3	Turkey
2	NCT02949908 (ClinicalTrials.gov)	February 9, 2017	17/10/2016	MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)	A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study ...	Multiple Sclerosis	Drug: Rebif	Merck KGaA, Darmstadt, Germany	Merck B.V., Netherlands	Terminated	18 Years	65 Years	All	2	Phase 4	Germany
3	NCT02823951 (ClinicalTrials.gov)	February 2016	3/3/2016	Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebi ...	Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebi ...	Relapsing-remitting Multiple Sclerosis	Drug: Rebif;Drug: Tecfidera	IMS HEALTH GmbH & Co. OHG	EMD Serono	Completed	18 Years	55 Years	All	479		United States;Canada
4	NCT02364986 (ClinicalTrials.gov)	January 2015	10/12/2014	Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Re ...	Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Re ...	Relapsing-remitting Multiple Sclerosis	Drug: Rebif ®;Drug: Avonex	PD Dr. Marcus Müller	BfARM, Bonn;DZNE, Bonn	Recruiting	18 Years	65 Years	Both	50	Phase 1	Germany
5	NCT02254304 (ClinicalTrials.gov)	December 31, 2014	29/9/2014	Effectiveness of Rebif®in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSm ...	Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in R ...	Relapsing Multiple Sclerosis;Clinically Isolated Syndrome	Drug: Rebif	Merck KGaA, Darmstadt, Germany	Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany	Completed	18 Years	65 Years	All	106	Phase 4	Germany
6	NCT02269930 (ClinicalTrials.gov)	October 2014	17/10/2014	Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif®(Interfe ...	An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterf ...	Multiple Sclerosis	Drug: peginterferon beta-1a;Drug: Rebif	Biogen Idec	NULL	Completed	18 Years	45 Years	Both	30	Phase 1	United States
7	NCT02117050 (ClinicalTrials.gov)	June 2014	15/4/2014	RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate	RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-la ...	Multiple Sclerosis	Drug: Rebif ®	EMD Serono	NULL	Terminated	18 Years	65 Years	All	1	Phase 4	United States
8	NCT02064816 (ClinicalTrials.gov)	May 31, 2014	13/2/2014	A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis	Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif ®	Merck KGaA, Darmstadt, Germany	NULL	Completed	18 Years	60 Years	All	200	Phase 4	Germany
9	EUCTR2013-004450-21-IT (EUCTR)	07/02/2014	12/12/2013	study to evaluate whether the administration of Rebif ® 44 three times a week in the morning can red ...	Multicenter, open-label, 12 weeks,phaseIV pRospectivE randomized study aimed at evaLuating whether s ...	relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ...	Trade Name: Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia Product Name: Rebif ®	Merck Serono S.p.A.	NULL	Not Recruiting			Female: yes Male: yes	218	Phase 4	Italy
10	NCT01791244 (ClinicalTrials.gov)	February 28, 2013	12/2/2013	A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life an ...	A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSuppor ...	Multiple Sclerosis;Relapsing-Remitting	Drug: Rebif ®	Merck KGaA	NULL	Completed	18 Years	N/A	All	93	Phase 4	Germany;Sweden

First Previous1 2 3 4 5…13Next Last